{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009485","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.085674+00:00","generated_at":"2026-06-17T18:42:18.152628+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ARS Pharma reports FY2022 net loss $34.7M; neffy NDA under FDA review, PDUFA mid-2023","bullets":["Net loss of $14.4M for Q4 2022 and $34.7M for full year 2022; cash & investments $274.4M as of Dec 31, 2022.","NDA for neffy (intranasal epinephrine) accepted by FDA; PDUFA target action date anticipated in mid-2023.","MAA for neffy also under review by EMA; company reacquired European rights.","R&D expenses $4.7M (Q4) and $18.4M (FY); G&A $10.7M (Q4) and $18.5M (FY).","Cash runway sufficient for at least three years; preparing for potential U.S. launch in 2023 if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009485","json":"https://secwatch.observer/filing/0000950170-23-009485.json","markdown":"https://secwatch.observer/filing/0000950170-23-009485.md","text":"https://secwatch.observer/filing/0000950170-23-009485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023009485/0000950170-23-009485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023009485/sbtx-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:42:18.152628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"511e655b015f8025106bd212e7ac06dc41a2d400","claim":"ARS Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: net income $34.7 million.","evidence_excerpt":"Net loss was $14.4 million for the quarter ended December 31, 2022, and $34.7 million for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023009485/0000950170-23-009485-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$34.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c86daf3888c5ac4b425766d7a003543efa3ffe21","claim":"ARS Pharmaceuticals, Inc. reported the quarter ended December 31, 2022 results: net income $14.4 million.","evidence_excerpt":"Net loss was $14.4 million for the quarter ended December 31, 2022, and $34.7 million for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023009485/0000950170-23-009485-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Net income","value":"$14.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}